About AVT
Browse Articles
Authors
Customer Services

Short communication

Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort

Belén Alejos, Inés Suárez-García, Jose Ignacio Bernardino, José Ramón Blanco, Maria Peñaranda, Azucena Bautista, Félix Gutiérrez, Inma Jarrín, Victoria Hernando, the CORIS cohort

Corresponding author name: Victoria Hernando
Corresponding author e-mail: vhernando@isciii.es

Citation: Antiviral Therapy 2020; 25:335-340
doi: 10.3851/IMP3380

Date accepted: 23 December 2020
Date published online: 20 January 2021

Abstract

Background: To compare effectiveness and safety of initial antiretroviral therapy (ART) among premenopausal and postmenopausal women living with HIV aged 45–60 years from the cohort of the Spanish HIV/AIDS Research Network (CoRIS) who initiated ART between 2004 and 2015.

Methods: Multivariable regression models were used to compare post- versus premenopausal women regarding viral suppression (≤50 copies/ml), change in CD4+ T-cell count and time to treatment change (TC) at 48 and 96 weeks after ART initiation.

Results: Among 230 women, 154 (67%) were premenopausal at ART initiation. The most frequent initial regimen was tenofovir disoproxil fumarate/emtricitabine/efavirenz prescribed in 49 (32%) premenopausal and 22 (29%) postmenopausal women. The proportion of TC was 35.7% and 30.3% at 48 weeks and 51.3% and 47.4% at 96 weeks, for pre- and postmenopausal women, respectively. There were no significant differences in CD4+ T-cell count changes from ART initiation, viral load suppression, time to TC or reason for TC between both groups. The main reason for TC was occurrence of an adverse event, followed by simplification, in both groups.

Conclusions: ART effectiveness and safety did not differ significantly between pre- and postmenopausal women.

<< BACK

Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.